Logo image of AGE

AGEX THERAPEUTICS INC (AGE) Stock Fundamental Analysis

NYSEARCA:AGE - NYSE Arca - US00848H2076 - Common Stock - Currency: USD

11.1  -1.5 (-11.9%)

Fundamental Rating

1

Overall AGE gets a fundamental rating of 1 out of 10. We evaluated AGE against 558 industry peers in the Biotechnology industry. AGE has a bad profitability rating. Also its financial health evaluation is rather negative. AGE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AGE has reported negative net income.
AGE had a negative operating cash flow in the past year.
In the past 5 years AGE always reported negative net income.
AGE had a negative operating cash flow in each of the past 5 years.
AGE Yearly Net Income VS EBIT VS OCF VS FCFAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

The Return On Assets of AGE (-115.07%) is worse than 82.31% of its industry peers.
The Return On Equity of AGE (-166.86%) is worse than 69.05% of its industry peers.
Industry RankSector Rank
ROA -115.07%
ROE -166.86%
ROIC N/A
ROA(3y)-291.66%
ROA(5y)-221.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGE Yearly ROA, ROE, ROICAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600 800

1.3 Margins

The Gross Margin of AGE (50.00%) is better than 80.27% of its industry peers.
In the last couple of years the Gross Margin of AGE has declined.
AGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.98%
GM growth 5Y-5.52%
AGE Yearly Profit, Operating, Gross MarginsAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K -30K

More info and screens

2

2. Health

2.1 Basic Checks

AGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGE remains at a similar level compared to 1 year ago.
AGE has a worse debt/assets ratio than last year.
AGE Yearly Shares OutstandingAGE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
AGE Yearly Total Debt VS Total AssetsAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

2.2 Solvency

AGE has an Altman-Z score of 49.65. This indicates that AGE is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AGE (49.65) is better than 96.94% of its industry peers.
AGE has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
AGE has a worse Debt to Equity ratio (0.08) than 64.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 49.65
ROIC/WACCN/A
WACC9.52%
AGE Yearly LT Debt VS Equity VS FCFAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M -20M

2.3 Liquidity

AGE has a Current Ratio of 0.36. This is a bad value and indicates that AGE is not financially healthy enough and could expect problems in meeting its short term obligations.
AGE has a Current ratio of 0.36. This is amonst the worse of the industry: AGE underperforms 96.26% of its industry peers.
A Quick Ratio of 0.36 indicates that AGE may have some problems paying its short term obligations.
With a Quick ratio value of 0.36, AGE is not doing good in the industry: 96.09% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.36
Quick Ratio 0.36
AGE Yearly Current Assets VS Current LiabilitesAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

AGE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.31%.
The Revenue has grown by 66.67% in the past year. This is a very strong growth!
The Revenue for AGE have been decreasing by -53.63% on average. This is quite bad
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)66.67%
Revenue growth 3Y-74.12%
Revenue growth 5Y-53.63%
Sales Q2Q%600%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AGE Yearly Revenue VS EstimatesAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGE Price Earnings VS Forward Price EarningsAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGE Per share dataAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGEX THERAPEUTICS INC

NYSEARCA:AGE (3/26/2024, 8:04:03 PM)

11.1

-1.5 (-11.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-29 2024-03-29/amc
Earnings (Next)05-13 2024-05-13/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners43.6%
Ins Owner Change0%
Market Cap421.25M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4212.45
P/FCF N/A
P/OCF N/A
P/B 50.03
P/tB 54.14
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.22
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.07%
ROE -166.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50%
FCFM N/A
ROA(3y)-291.66%
ROA(5y)-221.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.98%
GM growth 5Y-5.52%
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.36
Quick Ratio 0.36
Altman-Z 49.65
F-Score4
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)66.67%
Revenue growth 3Y-74.12%
Revenue growth 5Y-53.63%
Sales Q2Q%600%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.71%
OCF growth 3YN/A
OCF growth 5YN/A